$6.91M in average volume shows that Pacific Biosciences of California Inc (PACB) is heading in the right direction

Steve Mayer

On Monday, Pacific Biosciences of California Inc (NASDAQ: PACB) opened higher 14.08% from the last session, before settling in for the closing price of $1.42. Price fluctuations for PACB have ranged from $0.85 to $2.72 over the past 52 weeks.

Over the past five-year period, the drop rate of yearbook sales for the company of the Healthcare sector was -23.55%. Company’s average yearly earnings per share was noted -67.14% at the time writing. With a float of $266.29 million, this company’s outstanding shares have now reached $300.35 million.

Considering the fact that the conglomerate employs 575 people, you should pay attention to its efficiency factor.

Pacific Biosciences of California Inc (PACB) Insider Activity

A key investor’s attitude towards the stock of the Medical Devices industry is another important factor to consider. The insider ownership of Pacific Biosciences of California Inc is 11.35%, while institutional ownership is 56.84%. The most recent insider transaction that took place on Aug 18 ’25, was worth 35,182. In this transaction an insider of this company sold 26,836 shares at a rate of $1.31, taking the stock ownership to the 1,920,035 shares. Before that another transaction happened on Aug 18 ’25, when Company’s Officer proposed sale 26,836 for $1.31, making the entire transaction worth $35,174.

Pacific Biosciences of California Inc (PACB) Earnings and Forecasts

If we go through the results of last quarter, which was made public on 9/30/2024, the company posted -0.17 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -0.21) by 0.04. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.13 per share during the current fiscal year.

According to the Wall Street analysts, stocks earnings will be around -67.14% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 25.21% during the next five years compared to -23.55% drop over the previous five years of trading.

Pacific Biosciences of California Inc (NASDAQ: PACB) Trading Performance Indicators

Check out the current performance indicators for Pacific Biosciences of California Inc (PACB). In the past quarter, the stock posted a quick ratio of 6.02. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.12.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.27, a number that is poised to hit -0.15 in the next quarter and is forecasted to reach -0.53 in one year’s time.

Technical Analysis of Pacific Biosciences of California Inc (PACB)

News Daemon
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.